24×7 Emergency Care

1-8-31/1, Minister Road, Secunderabad, Telangana 500003

EMERGENCY:A known mitochondrial disease patient with a stroke-like episode, severe lactic acidosis, or rapidly progressive muscle weakness —call040-46324365immediately — 24 hours, 7 days— 24/7

NEUROMUSCULAR DISORDERS

Mitochondrial Myopathy Treatment in Hyderabad: When the Problem Is in the Cell's Power Plant — and Why the Diagnosis Changes Every Medication Decision

Expert diagnosis of MELAS, CPEO, MERRF, and Kearns-Sayre syndrome at KIMS Neuroscience, Secunderabad, Hyderabad — genetic testing, muscle biopsy, and metabolic management.

View Our Specialists

Mitochondrial myopathies are a heterogeneous group of genetic conditions caused by defects in the mitochondria — the cellular organelles responsible for aerobic ATP production. Because mitochondria are present in virtually every cell, mitochondrial dysfunction produces multi-system disease affecting the organs with the highest energy demands: skeletal muscle (weakness, exercise intolerance), cardiac muscle (cardiomyopathy, arrhythmia), brain neurons (seizures, stroke-like episodes, cognitive decline), retinal cells (visual loss, ophthalmoplegia), and cochlear cells (sensorineural hearing loss). Inheritance: mitochondrial DNA (mtDNA) mutations are maternally inherited — all mitochondria in the fertilised egg come from the mother. Nuclear DNA (nDNA) mutations causing mitochondrial dysfunction follow Mendelian patterns. Key syndromes: MELAS (m.3243A>G, stroke-like episodes + encephalopathy + lactic acidosis + myopathy), MERRF (A8344G, myoclonic epilepsy + ragged red fibres + ataxia), CPEO (bilateral ptosis + ophthalmoplegia, slowly progressive), KSS (CPEO + pigmentary retinopathy + cardiac conduction defects, pacemaker often required), Leigh syndrome (bilateral basal ganglia/brainstem lesions in infants). CRITICAL: Metformin CONTRAINDICATED (inhibits mitochondrial complex I, exacerbates lactic acidosis). Valproate CONTRAINDICATED (inhibits beta-oxidation). Ragged red fibres on Gomori trichrome stain are the pathognomonic biopsy finding.

Metformin CONTRAINDICATED — the most urgent drug safety message in India: Metformin — the most widely prescribed first-line diabetes medication in India — inhibits mitochondrial complex I and can precipitate life-threatening lactic acidosis in patients with mitochondrial disease. Many patients with MELAS, Leigh syndrome, or other mitochondrial conditions are also diabetic (diabetes is a feature of MELAS). If they receive standard metformin therapy for their diabetes before the mitochondrial diagnosis is made, they are at risk of metformin-induced lactic acidosis on top of their already-impaired oxidative phosphorylation. At KIMS: every patient suspected of mitochondrial disease has their medications reviewed and metformin is withdrawn immediately if present.
MELAS diagnosis clues — the constellation to recognise: MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes): stroke-like episodes in a young person (typically <40 years) with MRI lesions that DO NOT follow arterial vascular territories (crossing boundaries between MCA and PCA territories, or posterior predominant); sensorineural hearing loss; diabetes mellitus; short stature; maternal family history of any combination of these features. The m.3243A>G mutation in the mitochondrial tRNA gene (MT-TL1) accounts for 80% of MELAS cases. Elevated blood lactate and a raised lactate:pyruvate ratio (>20) support the diagnosis.
KSS — the cardiac pacemaker requirement: Kearns-Sayre syndrome: CPEO (bilateral progressive ptosis and ophthalmoplegia) + pigmentary retinopathy + cardiac conduction defects + onset before age 20. The cardiac conduction defects in KSS (heart block, bundle branch block, ventricular tachycardia) can cause sudden death. Every KSS patient requires cardiology referral and electrophysiological assessment. Pacemaker implantation is frequently required for symptomatic or significant conduction disease, and cannot wait for symptoms to develop because sudden death can be the first cardiac presentation. All caused by large-scale sporadic mtDNA deletions.
Maternal inheritance — cascade implications for the whole family: When a patient is diagnosed with a mitochondrial DNA mutation (e.g., m.3243A>G causing MELAS), the same mutation may be present in all maternal relatives: the patient's mother, siblings, maternal aunts and uncles, and their children. Heteroplasmy: the proportion of mutated mitochondria (heteroplasmy level) varies between tissues and between family members, explaining why affected family members may have very different levels of disease severity. At KIMS, the diagnosis of a maternally inherited mitochondrial mutation triggers cascade assessment of the patient's mother, maternal siblings, and any maternal-line children who may be at risk — particularly for cardiac and audiological involvement.
Ragged red fibres + COX-negative fibres — the biopsy triad: Gomori modified trichrome stain: ragged red fibres — muscle fibres with abnormal aggregations of mitochondria at the periphery appear as irregular red edges. These are pathognomonic for mitochondrial myopathy. COX (cytochrome c oxidase) stain: COX-negative fibres — muscle fibres that fail to stain for complex IV activity, reflecting mitochondrial respiratory chain failure in those fibres. Succinate dehydrogenase (SDH) stain: ragged blue fibres — the SDH equivalent showing mitochondrial proliferation. Finding ragged red fibres + COX-negative fibres on a muscle biopsy from a patient with the appropriate clinical picture confirms mitochondrial myopathy.
Exercise as treatment — counter-intuitive but evidence-based: Exercise intolerance is the dominant symptom of mitochondrial myopathy — making the recommendation to exercise feel counterintuitive. But aerobic exercise specifically increases mitochondrial biogenesis (the production of new mitochondria) and mitochondrial density in muscle cells. Regular submaximal aerobic exercise has been shown in multiple studies to improve exercise capacity, muscle function, and quality of life in mitochondrial myopathy. The principle: existing mitochondria cannot be repaired by exercise, but the body can be induced to produce more mitochondria in response to aerobic training. Dose: moderate-intensity aerobic exercise (50-70% VO₂max), 3-5 sessions per week, avoiding anaerobic exercise and high-intensity exertion that maximally stresses the impaired oxidative phosphorylation pathway.
Valproate CONTRAINDICATED — the seizure drug that worsens mitochondrial disease: Valproate (sodium valproate), widely used in India for epilepsy and seizure management, inhibits mitochondrial beta-oxidation (fatty acid metabolism). In patients with mitochondrial disease — where oxidative phosphorylation is already impaired — valproate can precipitate or worsen hepatic failure, lactic acidosis, and encephalopathy. MERRF patients and other mitochondrial disease patients with epilepsy must not receive valproate. Safe alternatives for seizure management in mitochondrial disease: levetiracetam, lamotrigine, lacosamide. This substitution must be made at KIMS whenever a mitochondrial patient is on valproate.

About This Condition

Mitochondrial Disease at a Glance

The essential concepts that determine how mitochondrial disease is recognised, inherited, and — crucially — safely treated.

What they are

A group of genetic conditions caused by defects in the mitochondria — the cell's energy-producing organelles. Because mitochondria power every cell in the body, mitochondrial disease can affect muscle, brain, heart, eyes, ears, and endocrine glands simultaneously — producing the characteristic multi-system involvement that makes these conditions diagnostically challenging.

The energy failure concept

Mitochondria convert nutrients into ATP (adenosine triphosphate) — the universal energy currency of the cell. When mitochondria are defective, the cells with the highest energy demands are the first to fail: skeletal muscle (causing weakness and exercise intolerance), cardiac muscle (causing cardiomyopathy and arrhythmia), brain neurons (causing seizures, stroke-like episodes, and cognitive decline), retinal cells (causing visual loss and ophthalmoplegia), and cochlear cells (causing hearing loss).

Inheritance

Mitochondrial DNA (mtDNA) mutations are inherited maternally — all mitochondria in the fertilised egg come from the mother. This means an affected mother passes the mutation to all her children, but an affected father passes it to none. Nuclear DNA (nDNA) mutations affecting mitochondrial function are inherited in standard Mendelian patterns (autosomal recessive most commonly in children, autosomal dominant in some adult forms).

The key diagnostic clue

A patient with muscle weakness combined with any two of the following: unexplained sensorineural hearing loss, diabetes mellitus, maternal family history of the same combination, short stature, stroke-like episodes in a young person, or ptosis with eye movement disorder — should be evaluated for mitochondrial disease at KIMS.

The critical drug contraindication

Metformin — the most widely prescribed diabetes medication in India — is CONTRAINDICATED in mitochondrial disease because it inhibits mitochondrial complex I and exacerbates lactic acidosis. At KIMS, every patient suspected of mitochondrial disease has their medications reviewed, and metformin is withdrawn immediately if present.

Emergency

040-46324365

Appointment

040-44885000

About This Condition

The Condition That Affects the Organs That Need Energy Most

A 24-year-old woman in Hyderabad has had three episodes of what appeared to be strokes over two years. Each time, she developed sudden left-sided weakness, headache, and confusion. Each time, the neurologist found an area of signal change on MRI — but the stroke did not follow the territory of any single blood vessel. Her ECG has repeatedly shown a short PR interval. She has had type 1 diabetes since age 18 and has a profound sensorineural hearing loss in her right ear that appeared at 20. Her mother has similar hearing loss and diabetes, and her maternal aunt died of heart failure at 48.

At KIMS Neuroscience, this constellation is read immediately. Stroke-like episodes in a young woman, MRI lesions crossing vascular territories, sensorineural hearing loss, diabetes, cardiac conduction abnormality, and a maternal family history of the same combination — this is MELAS syndrome: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes. A blood test for the m.3243A>G mutation in the mitochondrial tRNA gene is sent that day. The result confirms MELAS.

Mitochondrial myopathies are among the most clinically diverse conditions in all of neurology. Because mitochondria are present in virtually every cell and the dysfunction affects all energy-dependent organs simultaneously, the clinical presentation can be dominated by muscle symptoms, or brain symptoms, or cardiac symptoms, or eye symptoms — or any combination. This diversity is precisely why mitochondrial disease is so commonly missed, attributed to multiple separate conditions, or mismanaged.

In Hyderabad and across India, mitochondrial disease faces two specific challenges that KIMS addresses directly: first, metformin — the standard first-line diabetes drug in India — is contraindicated in mitochondrial disease and can precipitate life-threatening lactic acidosis in these patients; second, the maternal inheritance pattern means that a diagnosis in one patient implies risk for the entire maternal line of the family, and cascade testing is essential.

Book a Consultation

Speak directly with our mitochondrial disease specialist team. No referral required. Monday to Saturday.

040-44885000Emergency line: 040-46324365

Understanding the Disease

The Major Mitochondrial Syndromes

Mitochondrial disease is not a single condition — it is a family of disorders grouped by which tissues are most prominently affected and which genetic mutation is responsible. The most commonly encountered syndromes at KIMS are:

MELAS

m.3243A>G (80% of cases) in MT-TL1 gene

Stroke-like episodes before age 40, encephalopathy, seizures, lactic acidosis, myopathy, sensorineural hearing loss, diabetes, cardiomyopathy, short stature. Most common maternally inherited mitochondrial disorder.

MERRF

tRNALys A8344G in MT-TK gene

Myoclonic epilepsy (jerking seizures), ragged red fibers on muscle biopsy, progressive ataxia, hearing loss, peripheral neuropathy, cardiomyopathy with WPW syndrome.

CPEO

Large-scale mtDNA deletions; also nDNA POLG, TWNK genes

Chronic progressive external ophthalmoplegia: bilateral ptosis and eye movement paralysis (ophthalmoplegia). Often the only feature for years. Can be part of Kearns-Sayre syndrome.

KSS

Large-scale mtDNA deletions (sporadic)

CPEO + pigmentary retinopathy + cardiac conduction defects (heart block) + ataxia, onset before age 20. Cardiac involvement can cause sudden death — requires pacemaker.

Leigh Syndrome

nDNA or mtDNA mutations, various genes (SURF1, SDHA, SCO2, etc.)

Subacute necrotising encephalopathy in infants and children. Basal ganglia and brainstem involvement. Characteristic bilateral symmetric lesions on MRI brain. Often fatal in early childhood. Autosomal recessive — relevant in consanguineous South Indian families.

Mitochondrial myopathy (pure)

Variable nDNA or mtDNA mutations

Proximal muscle weakness and exercise intolerance without prominent neurological, ocular, or hearing features. Ragged red fibers on muscle biopsy. Elevated blood/CSF lactate.

Recognising Mitochondrial Myopathy

Clinical Features — What Mitochondrial Myopathy Feels Like

The muscle symptoms of mitochondrial myopathy are characteristic. The pattern of energy failure in muscle produces features that are distinct from other myopathies and that, when recognised, point directly to the mitochondrial diagnosis.

Exercise intolerance — the most common symptom

Disproportionate fatigue with physical activity — out of proportion to the effort required. Patients cannot sustain physical effort that a healthy person of the same age would find manageable. After brief exercise, they need prolonged rest to recover. This is the energy failure of mitochondrial dysfunction: the muscle rapidly depletes its ATP reserve, lactic acid accumulates (because anaerobic metabolism compensates for the failing aerobic pathway), and muscle function temporarily collapses.

Proximal muscle weakness

Progressive weakness of the shoulder and hip girdle muscles — similar in distribution to other myopathies. Neck flexor weakness is characteristic in mitochondrial myopathy and affected earlier than in most other conditions. The weakness is typically mild to moderate rather than the severe weakness seen in DMD or IMNM.

Ptosis and ophthalmoplegia — the eye signs

Drooping eyelids (ptosis) and paralysis of eye movements (ophthalmoplegia) are the most specific ocular signs of mitochondrial disease. In CPEO and KSS, the eye movement paralysis is bilateral, symmetric, and slowly progressive — producing a fixed, staring gaze as the years pass. Because both eyes are equally affected, patients often do not notice double vision — the brain suppresses the double image. The ptosis and ophthalmoplegia of mitochondrial disease are chronic and progressive, distinguishing them from the fatigable ptosis of Myasthenia Gravis.

Sensorineural hearing loss

High-frequency sensorineural hearing loss — affecting the cochlea — is present in the majority of MELAS patients and in many other mitochondrial disorders. It typically develops in the teens to 20s, often before other features of the syndrome. In India, progressive hearing loss in a young person is commonly attributed to acoustic trauma or idiopathic causes. At KIMS, unexplained sensorineural hearing loss in a young person with any other feature of metabolic disease (diabetes, short stature, maternal family history of similar) prompts evaluation for mitochondrial disease.

Lactic acidosis

Elevated blood lactate — produced when failing mitochondrial oxidative phosphorylation forces cells to rely on anaerobic glycolysis. Serum lactate is elevated at rest in some mitochondrial patients and rises excessively with minor exercise. In MELAS stroke-like episodes, serum and CSF lactate are markedly elevated. Clinically, lactic acidosis produces nausea, fatigue, muscle pain, and rapid breathing. In severe cases it causes a life-threatening metabolic emergency.

Stroke-like episodes — the MELAS hallmark

Sudden neurological deficits — hemiparesis, visual loss, aphasia, cortical blindness — that resemble ischaemic stroke clinically but differ on MRI: the lesions cross vascular territories (they do not follow the supply zone of a single cerebral artery), they are most common in the posterior brain (occipital and parietal lobes), and they slowly spread and partially resolve over days to weeks — behaviour unlike a standard stroke. On MRI, the diffusion characteristics differ from ischaemic stroke: the apparent diffusion coefficient (ADC) is increased in MELAS lesions, not decreased as in ischaemia. This MRI distinction is critical — at KIMS, a young person with a “stroke” that crosses vascular territories is immediately considered for MELAS.

Cardiomyopathy and conduction defects

Hypertrophic or dilated cardiomyopathy occurs in mitochondrial disease because cardiac muscle has a very high energy demand. In KSS, cardiac conduction defects — progressive heart block — are a specific feature that can cause sudden cardiac death, requiring pacemaker implantation. In MELAS, both hypertrophic cardiomyopathy and Wolff-Parkinson-White (WPW) syndrome (an accessory conduction pathway causing dangerous tachyarrhythmias) are recognised associations. At KIMS, ECG and echocardiography are performed for every mitochondrial disease patient at diagnosis.

India-Specific Context

The Metformin Danger and the Maternal Family

Metformin — The Most Important Drug Contraindication in India

METFORMIN IS CONTRAINDICATED IN MITOCHONDRIAL DISEASE:

Metformin (sold in India under multiple brand names including Glucophage, Glycomet, Janumet) is the first-line oral diabetes drug prescribed to hundreds of millions of people in India. It works partly by inhibiting mitochondrial complex I. In a patient with mitochondrial disease — whose mitochondria are already dysfunctional — metformin further impairs energy production and can precipitate life-threatening lactic acidosis.

Several mitochondrial patients in India have presented to KIMS in metabolic crisis following metformin initiation for their diabetes, without the prescribing physician being aware of the underlying mitochondrial diagnosis.

At KIMS, every patient suspected of mitochondrial disease has their medication list reviewed on the day of assessment, and metformin is withdrawn immediately if present. Alternative diabetes management (insulin, DPP-4 inhibitors, SGLT2 inhibitors with caution) is arranged.

ALERT CARD: Every confirmed mitochondrial disease patient at KIMS receives a written medication alert card naming metformin and valproate as drugs that must not be prescribed without specialist review.

Other Contraindicated and High-Risk Drugs in Mitochondrial Disease

• Valproate (sodium valproate): Used widely in India for epilepsy and mood disorders. Inhibits mitochondrial β-oxidation and depletes carnitine. Associated with hepatotoxicity and increased metabolic crisis risk in mitochondrial disease. In MELAS patients with seizures, valproate must be avoided — levetiracetam, lamotrigine, or other alternatives are used.

• Statins: Can exacerbate mitochondrial myopathy and lactic acidosis. Used with caution; the risk-benefit calculation is discussed individually.

• Aminoglycoside antibiotics: Can worsen mitochondrial hearing loss, particularly in patients with the m.1555A>G mutation (a specific mitochondrial mutation causing susceptibility to aminoglycoside-induced deafness, present in a subset of Indian patients with hearing loss).

• Contrast media (iodinated): Used with caution in mitochondrial patients with renal involvement or lactic acidosis tendency.

The Maternal Family Pattern — Why Cascade Testing Matters

When MELAS, MERRF, or another mtDNA mutation is identified at KIMS, the inheritance implications are immediately addressed.

Because mtDNA is maternally inherited, the mother of the affected patient is either the source of the mutation or herself affected (sometimes mildly or asymptomatically — due to heteroplasmy, described below).

All maternal relatives — siblings, maternal aunts and uncles, maternal cousins — may carry the mutation.

At KIMS, we actively counsel the affected patient's family about the implications, and cascade testing with a blood or urine sample is offered to all at-risk maternal relatives.

Heteroplasmy — Why Severity Varies Within the Same Family

Mitochondria exist in hundreds of copies per cell. In mitochondrial disease, some copies carry the mutation (mutant mtDNA) and some are normal (wild-type mtDNA).

The proportion of mutant copies in a cell is called the heteroplasmy level. When the mutant proportion exceeds a threshold — which varies by tissue and by the specific mutation — disease manifests.

Below the threshold, the individual may be a carrier with no or minimal symptoms.

This explains why a mother with 20% mutant mtDNA may be asymptomatic while her daughter, who inherited 80% mutant mtDNA, has severe MELAS. The same mutation produces a spectrum of severity across the family.

Leigh Syndrome and Consanguinity in South India

Leigh syndrome — caused by nuclear DNA mutations affecting the mitochondrial respiratory chain — is autosomal recessive and disproportionately common in consanguineous families.

In South India, including Telangana and Andhra Pradesh, where consanguineous marriage is culturally common, Leigh syndrome appears in first-cousin marriages where both parents carry a copy of the same nuclear mitochondrial gene mutation.

At KIMS, a child from a consanguineous family presenting with psychomotor regression, brainstem symptoms, and the characteristic symmetric basal ganglia lesions on MRI is immediately evaluated for Leigh syndrome.

Diagnosis at KIMS

Diagnosis at KIMS — The Tests Required

Blood lactate and pyruvate — the metabolic screen

Fasting blood lactate and pyruvate are measured at rest and, where safe, after supervised mild exercise. Elevated blood lactate (>2.5 mmol/L at rest, rising excessively with exercise) is a key metabolic marker. Lactate:pyruvate ratio above 20 suggests a defect in oxidative phosphorylation. CSF lactate is measured via lumbar puncture in suspected MELAS and in children with encephalopathy. Urinary organic acids are analysed for pattern of metabolite accumulation.

Genetic testing — mtDNA and nDNA panel

Blood or urine sample for common mtDNA point mutations (m.3243A>G for MELAS, m.8344A>G for MERRF, m.8993T>G/C for NARP/MILS, m.1555A>G for aminoglycoside-induced deafness). Muscle biopsy for mtDNA deletion analysis (for CPEO and KSS, where the deletions are often not detectable in blood). Comprehensive nuclear mitochondrial gene panel by next-generation sequencing when common mtDNA mutations are not found — covers over 300 nuclear genes involved in mitochondrial function.

Muscle biopsy — ragged red fibres and COX-negative fibres

The defining histological features of mitochondrial myopathy on muscle biopsy are: (1) Ragged red fibres on modified Gomori trichrome stain — fibres with abnormal mitochondrial proliferation at the periphery that stain red, while the central myofibrillar area appears disrupted. The “ragged” appearance is named for the irregular red border. (2) COX-negative fibres — muscle fibres that fail to stain for cytochrome c oxidase (complex IV), reflecting mitochondrial respiratory chain dysfunction. (3) Increased succinate dehydrogenase (SDH) staining in mitochondrial-rich fibres. At KIMS, muscle biopsy is processed with the full histochemical panel required for mitochondrial diagnosis.

MRI brain

In MELAS: stroke-like lesions in the posterior brain (occipital and parietal lobes), crossing vascular territories, with increased ADC on diffusion-weighted imaging (distinguishing them from ischaemic strokes where ADC is reduced). Basal ganglia calcifications on CT. In Leigh syndrome: bilateral symmetric lesions in the basal ganglia and brainstem. Magnetic resonance spectroscopy (MRS) shows elevated lactate peaks within lesions. In MERRF and other syndromes: variable, often non-specific white matter changes.

Multi-system baseline assessment

At confirmed mitochondrial disease diagnosis at KIMS: ECG and echocardiogram (cardiac involvement); audiometry (sensorineural hearing loss); ophthalmology review with electroretinogram for pigmentary retinopathy (KSS); endocrine panel (HbA1c, thyroid function); pulmonary function tests (respiratory muscle involvement); neuropsychological assessment (cognitive involvement in MELAS and MERRF).

Treatment

Treatment — Energy Support, Drug Safety, and Multi-System Care

Treatment Strategy

Mitochondrial Supplement Therapy

No therapy reverses the underlying mitochondrial DNA defect. Management targets the biochemical consequences of energy failure. The commonly used mitochondrial supplements at KIMS, with the caveat that the evidence for most remains observational rather than from large randomised trials, are prescribed on an individualised basis based on the patient's specific syndrome and biochemical profile.

Safety First

Avoiding Drug-Induced Harm

In mitochondrial disease, the wrong drug can be more dangerous than the disease itself. Metformin and valproate can precipitate life-threatening metabolic crises. At KIMS, every confirmed mitochondrial disease patient receives a written medication alert card naming metformin and valproate as drugs that must not be prescribed without specialist review.

Mitochondrial Supplements

Energy support therapies prescribed at KIMS

•

Coenzyme Q10 (CoQ10) — an electron carrier in the mitochondrial respiratory chain. CoQ10 supplementation has the most consistent evidence across mitochondrial disorders. Typical dose: 200–600mg/day in divided doses. Well tolerated. At KIMS, CoQ10 is prescribed for all confirmed mitochondrial myopathy patients

•

L-Carnitine — facilitates transport of fatty acids into mitochondria for β-oxidation. Secondary carnitine deficiency is common in mitochondrial disease. Typical dose: 1–3g/day in divided doses. Particularly important in children

•

Riboflavin (Vitamin B2) — a precursor of FAD, an essential coenzyme for complexes I and II. Supplementation in patients with complex I or II deficiency.

•

Thiamine (Vitamin B1) — important for pyruvate dehydrogenase function. Supplemented in patients with abnormal pyruvate metabolism

•

Arginine and citrulline — specific to MELAS stroke-like episodes: Intravenous L-arginine (0.5g/kg IV) is given during the acute stroke-like episode to increase nitric oxide production and improve cerebrovascular blood flow. Oral arginine or citrulline supplementation between episodes may reduce the frequency of stroke-like episodes. This is the most evidence-based acute treatment in mitochondrial disease. Available at KIMS Neuro-ICU

Contraindicated & High-Risk Drugs

Drugs that must not be prescribed without specialist review

•

Metformin (sold in India as Glucophage, Glycomet, Janumet) — CONTRAINDICATED. Inhibits mitochondrial complex I and further impairs energy production in already dysfunctional mitochondria, precipitating life-threatening lactic acidosis. Withdrawn immediately at KIMS in any patient suspected of mitochondrial disease

•

Valproate (sodium valproate) — Used widely in India for epilepsy and mood disorders. Inhibits mitochondrial β-oxidation and depletes carnitine. Associated with hepatotoxicity and increased metabolic crisis risk in mitochondrial disease. In MELAS patients with seizures, valproate must be avoided — levetiracetam, lamotrigine, or other alternatives are used

•

Statins — Can exacerbate mitochondrial myopathy and lactic acidosis. Used with caution; the risk-benefit calculation is discussed individually

•

Aminoglycoside antibiotics — Can worsen mitochondrial hearing loss, particularly in patients with the m.1555A>G mutation (a specific mitochondrial mutation causing susceptibility to aminoglycoside-induced deafness, present in a subset of Indian patients with hearing loss)

•

Contrast media (iodinated) — Used with caution in mitochondrial patients with renal involvement or lactic acidosis tendency

Multi-System Care

Diabetes Management in Mitochondrial Disease

Insulin — first-line for MELAS-associated diabetes, as β-cell function declines over time and patients often progress to insulinopenia. Metformin is ABSOLUTELY CONTRAINDICATED. DPP-4 inhibitors (sitagliptin, vildagliptin) — can be used cautiously without the lactic acidosis risk of metformin. Dietary management — low-glycaemic-index diet reduces the metabolic demand on mitochondria. Ketogenic diet in selected cases of Leigh syndrome and other childhood mitochondrial encephalopathies.

Multi-System Care

Cardiac Management

Annual ECG and echocardiogram for all mitochondrial disease patients. Pacemaker for KSS with progressive heart block — not optional; sudden cardiac death is the risk without it. ICD for KSS or MELAS patients with documented ventricular arrhythmia. WPW syndrome in MELAS — monitored by cardiology; ablation if symptomatic.

Neurological Care

Seizure Management in MELAS

Levetiracetam — preferred anti-seizure medication in mitochondrial disease; no mitochondrial toxicity. Lamotrigine, topiramate — acceptable alternatives. Valproate — AVOID: mitochondrial toxicity, hepatotoxicity risk, carnitine depletion. Status epilepticus in MELAS — treat as standard status epilepticus plus IV arginine for the stroke-like component.

Lifestyle Care

Exercise and Physiotherapy

Moderate aerobic exercise is encouraged in mitochondrial myopathy and has evidence of benefit: it increases mitochondrial biogenesis (the formation of new mitochondria) and improves exercise tolerance. At KIMS, a supervised exercise programme is prescribed — starting at low intensity and building gradually. High-intensity anaerobic exercise is avoided as it worsens lactic acid accumulation. Swimming and cycling are well tolerated.

Related Conditions

Mitochondrial Myopathy belongs to the family of neuromuscular disorders evaluated and managed at KIMS Neuroscience:

Muscular Dystrophy Neuromuscular Disorders (Master)

FAQs

Frequently Asked Questions

MELAS is caused by a mutation in mitochondrial DNA (mtDNA), which is inherited only from the mother. This means: if your mother has MELAS, she passed her mtDNA — which carries the m.3243A>G or another mutation — to all of her children, including you. However, because of heteroplasmy (each cell contains a mixture of normal and mutant mtDNA), the amount of mutant mtDNA you inherited may be higher or lower than your mother's, and your symptoms — if any — may be more or less severe. Some people with this mutation are mildly affected (hearing loss and diabetes only); others have full MELAS syndrome. At KIMS, we offer genetic testing from a blood or urine sample to determine your heteroplasmy level and guide counselling. If you are a woman, your children are also at risk of inheriting the mutation from you. Please call 040-44885000 for a genetic counselling appointment.

No — metformin is contraindicated in mitochondrial disease and must not be started. This is one of the most important drug safety points in mitochondrial medicine. Metformin works partly by inhibiting mitochondrial complex I — the same respiratory chain complex that is dysfunctional in many mitochondrial disorders. In a patient with mitochondrial disease, metformin further impairs energy production and can precipitate life-threatening lactic acidosis. Several mitochondrial patients have been admitted to KIMS in metabolic crisis after metformin initiation. Please contact your GP immediately and ask that metformin not be prescribed. Then call KIMS Neuroscience on 040-44885000 so that we can arrange appropriate diabetes management — insulin or metformin-free oral agents are the alternatives. At KIMS, every confirmed mitochondrial disease patient receives a written medication alert card for their wallet, listing metformin and valproate as drugs that must not be prescribed without specialist clearance.

This is an urgent situation that requires immediate specialist evaluation at KIMS. MELAS stroke-like episodes are not the same as standard ischaemic strokes, and the treatment is different. The episodes are caused by metabolic energy failure in neurons and cerebrovascular dysfunction, not by blood clots. Standard stroke treatment (aspirin, anticoagulation) does not help. What does help during an acute MELAS stroke-like episode: intravenous L-arginine, seizure control (the episodes are frequently accompanied by seizures), and supportive metabolic management. At KIMS, we also immediately arrange: blood and CSF lactate measurement, genetic testing for the m.3243A>G and other MELAS-causing mutations, echocardiogram and ECG for cardiac involvement, and comprehensive metabolic panel. Please call 040-44885000 for an urgent appointment. If your son is currently having a stroke-like episode, call 040-46324365 immediately.

The combination of bilateral, slowly progressive ptosis (drooping eyelids) and ophthalmoplegia (restricted eye movements) — particularly when both eyes are equally affected and there is no fluctuation or fatigability — is the clinical picture of Chronic Progressive External Ophthalmoplegia (CPEO), one of the most common presentations of mitochondrial myopathy. In CPEO, both eyes move together symmetrically into the restricted position, so patients often do not notice double vision (unlike other causes of eye movement problems). The ptosis slowly worsens over years. CPEO can occur in isolation or as part of Kearns-Sayre syndrome (when accompanied by pigmentary retinopathy and cardiac conduction disease — which can cause sudden death without a pacemaker). At KIMS, the assessment includes ophthalmology review with electroretinogram, ECG (looking for heart block), genetic testing for large-scale mtDNA deletions, and muscle biopsy if needed. Please call 040-44885000 urgently if you also have any dizziness, palpitations, or blackouts — these could indicate the cardiac component of KSS.

Leigh syndrome is a severe mitochondrial disorder of the brain, most commonly affecting infants and young children. It is caused by mutations in nuclear or mitochondrial genes that disrupt the mitochondrial respiratory chain, producing characteristic bilateral symmetric lesions in the basal ganglia and brainstem on MRI. The clinical picture is one of psychomotor regression — a child who was developing normally begins to lose milestones, develops brainstem symptoms (swallowing difficulty, abnormal eye movements, breathing irregularities), and progresses to severe neurological impairment. The prognosis in classical Leigh syndrome is unfortunately poor — most children follow a progressive course, though the rate of progression varies considerably depending on the specific genetic mutation and the degree of respiratory chain deficiency. At KIMS, management is supportive and metabolic: CoQ10, thiamine, riboflavin, and carnitine supplementation; seizure management with appropriate medications; nutritional support; respiratory physiotherapy; and family genetic counselling. Genetic identification of the specific mutation is important for family planning (autosomal recessive Leigh syndrome carries a 25% recurrence risk). Please call 040-44885000 for a comprehensive Leigh syndrome assessment and genetic counselling appointment.

No — moderate aerobic exercise is beneficial in mitochondrial myopathy and is specifically recommended at KIMS. The concern about exercise in mitochondrial disease is outdated. Current evidence shows that moderate endurance exercise increases mitochondrial biogenesis — it stimulates the formation of new mitochondria in muscle cells — and improves exercise tolerance, muscle strength, and quality of life in patients with mitochondrial myopathy. The key is the intensity: moderate, sustained aerobic exercise (such as swimming, cycling, or brisk walking) is beneficial. High-intensity anaerobic exercise — sprinting, heavy weightlifting, exercise to exhaustion — is problematic because it generates lactic acid faster than the impaired mitochondria can process it. At KIMS, a physiotherapy-supervised exercise programme is prescribed, starting at low intensity and building gradually according to tolerance. The programme is individualised based on your specific syndrome and current functional capacity. Call 040-44885000.

Yes — and ideally before any of them are prescribed metformin for diabetes, started on valproate for any reason, or given aminoglycoside antibiotics for an infection. The pattern you describe — maternal transmission of hearing loss and diabetes across two generations — is highly suggestive of MELAS or another maternally inherited mitochondrial disorder, even if no one has had a stroke-like episode. The m.3243A>G mutation causes a spectrum of severity, and many carriers have only hearing loss and diabetes without the full MELAS syndrome. Testing from a blood or urine sample can identify the mutation and measure the heteroplasmy level in each family member. This is important for: (1) preventing drug harm (metformin, valproate, aminoglycosides); (2) identifying those at risk of stroke-like episodes who need a clear emergency plan; (3) cardiac screening for those with significant heteroplasmy levels; (4) genetic counselling for childbearing-age women who would pass the mutation to all their children. Please bring your family to KIMS — we can arrange family testing efficiently at one coordinated appointment. Call 040-44885000.

Fact	Details
Maternal inheritance	mtDNA mutations passed from mother to ALL children · Father with mtDNA mutation: no transmission risk · Heteroplasmy: variable severity across family members · Cascade testing of entire maternal line at KIMS
6 key syndromes	MELAS: stroke-like + hearing loss + diabetes + m.3243A>G · MERRF: myoclonic epilepsy + ataxia · CPEO: bilateral ptosis + ophthalmoplegia · KSS: CPEO + retinopathy + cardiac (pacemaker required) · Leigh: bilateral BG/brainstem lesions in infants · Pure mitochondrial myopathy: exercise intolerance + ragged red fibres
Critical drug contraindications	Metformin: CONTRAINDICATED (inhibits complex I, exacerbates lactic acidosis) · Valproate: CONTRAINDICATED (inhibits beta-oxidation, hepatic failure risk) · Review all medications at diagnosis
Biopsy triad	Ragged red fibres (Gomori trichrome) · COX-negative fibres · Ragged blue fibres (SDH) · Pathognomonic for mitochondrial myopathy
Lactate/pyruvate ratio	>20 suggests mitochondrial respiratory chain defect · Elevated in MELAS and other mtDNA disorders · CSF lactate more sensitive than blood in CNS-dominant presentations
Treatment	Aerobic exercise (increases mitochondrial biogenesis) · Coenzyme Q10, riboflavin (supportive) · Pacemaker for KSS cardiac disease · Avoid metformin and valproate · Levetiracetam/lamotrigine for seizures
Contact	040-44885000 · Emergency (stroke-like episode or lactic acidosis): 040-46324365

Weakness after minimal exercise. Hearing loss that no one has explained. Diabetes in a young person. A stroke in a 25-year-old whose MRI does not look like a regular stroke. A family pattern of the same problems passed through the mother's side. These are the signals of mitochondrial disease — and the drug you are taking for your diabetes may be the most dangerous thing in the room.

At KIMS Neuroscience, Secunderabad, Hyderabad, every patient presenting with suspected mitochondrial disease receives the structured assessment: blood and CSF lactate, mitochondrial genetic panel (common mtDNA point mutations and nDNA panel), muscle biopsy with ragged red fibre and COX-negative fibre analysis, MRI brain, and the full multi-system baseline covering cardiac, audiology, ophthalmology, and endocrine. Every KIMS mitochondrial patient receives a medication alert card: metformin and valproate are contraindicated. Cascade testing for the maternal family is arranged as part of the initial consultation.

040-44885000

International enquiries: info@kimsneurosciences.com